Eye scans could reveal hidden clues about MS treatment success

NCT ID NCT06864936

First seen Oct 31, 2025 · Last updated May 02, 2026 · Updated 23 times

Summary

This study tests whether a special eye scan (OCT) can detect changes in immune cells in the retina of people with multiple sclerosis (MS) who start a new medication called ublituximab (Briumvi). Researchers will compare 15 people starting ublituximab with 15 people on stable MS therapy. The goal is to find new biomarkers that show how well the treatment is working, without needing invasive tests.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS (MS) - RELAPSING-REMITTING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Maryland, Baltimore

    Baltimore, Maryland, 21201, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.